Clinical Trials - October 25, 2013
Phase III clinical trial in NSCLC patients
AstraZeneca has announced the first patient randomized in a phase III clinical trial for selumetinib, an oral, potent, selective MEK inhibitor, being investigated as second-line therapy in patients with advanced or metastatic non-small-cell lung cancer (NSCLC) whose tumors are KRAS mutation-positive. In 2003, Array BioPharma invented and licensed the worldwide rights to develop and commercialize […]